GENET-news
To stay informed you can subscribe to the GENET-news list.
2009-09-02 | permalink
Monsanto backs French biotech firm Cellectis
Cellectis, a $150 million French biotechnology company that specializes in ”gene clipping”--or the targeted removal, insertion or manipulation of genetic material--has just landed its biggest backer yet in the shape of Monsanto. The $45 billion agribusiness leviathan is paying Cellectis 3 million euros ($4.3 million) upfront to access the French firm’s proprietary technology, and is also buying a 1% stake for 1 million euros ($1.4 million) to beef up its investment.
Overview
News
2009-09-02 | permalink
Monsanto backs French biotech firm Cellectis
Cellectis, a $150 million French biotechnology company that specializes in ”gene clipping”--or the targeted removal, insertion or manipulation of genetic material--has just landed its biggest backer yet in the shape of Monsanto. The $45 billion agribusiness leviathan is paying Cellectis 3 million euros ($4.3 million) upfront to access the French firm’s proprietary technology, and is also buying a 1% stake for 1 million euros ($1.4 million) to beef up its investment.
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.